Strides Pharma Science Limited (STAR.NS)
INR 701.9
(1.52%)
INR 701.9
(1.52%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 37.68 Billion INR | -15.62% |
| 2022 | 44.65 Billion INR | -2.77% |
| 2021 | 45.92 Billion INR | 9.32% |
| 2020 | 42.01 Billion INR | 18.1% |
| 2019 | 35.57 Billion INR | -31.65% |
| 2018 | 52.03 Billion INR | 32.26% |
| 2017 | 39.34 Billion INR | -24.95% |
| 2016 | 52.42 Billion INR | 10.29% |
| 2015 | 47.53 Billion INR | 259.41% |
| 2014 | 13.22 Billion INR | 30.1% |
| 2013 | 10.16 Billion INR | -62.34% |
| 2012 | 26.99 Billion INR | -33.29% |
| 2011 | 40.46 Billion INR | 37.72% |
| 2010 | 29.38 Billion INR | 37.28% |
| 2009 | 21.4 Billion INR | 23.59% |
| 2008 | 17.31 Billion INR | -0.47% |
| 2007 | 17.39 Billion INR | 118.53% |
| 2006 | 7.96 Billion INR | 35.1% |
| 2005 | 5.89 Billion INR | 79.15% |
| 2004 | 3.28 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 37.74 Billion INR | 282.2% |
| 2024 Q1 | -20.71 Billion INR | -154.98% |
| 2023 Q2 | 43.44 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 37.68 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 37.68 Billion INR | -15.62% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 44.65 Billion INR | 0.0% |
| 2022 FY | 44.65 Billion INR | -2.77% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 45.43 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 45.92 Billion INR | 9.32% |
| 2021 Q2 | 44.09 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 45.92 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 42.01 Billion INR | 18.1% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 38.93 Billion INR | 0.0% |
| 2020 Q4 | 42.01 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 35.57 Billion INR | -31.65% |
| 2019 Q4 | 35.57 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 33.2 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 52.03 Billion INR | 32.26% |
| 2018 Q4 | 52.03 Billion INR | 0.0% |
| 2018 Q2 | 46.98 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 56.19 Billion INR | 0.0% |
| 2017 FY | 39.34 Billion INR | -24.95% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 39.34 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 52.42 Billion INR | 0.0% |
| 2016 FY | 52.42 Billion INR | 10.29% |
| 2016 Q2 | 51.61 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 47.53 Billion INR | 0.0% |
| 2015 Q2 | 29.97 Billion INR | 0.0% |
| 2015 FY | 47.53 Billion INR | 259.41% |
| 2014 FY | 13.22 Billion INR | 30.1% |
| 2014 Q4 | 13.22 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 10.16 Billion INR | -62.34% |
| 2012 FY | 26.99 Billion INR | -33.29% |
| 2011 FY | 40.46 Billion INR | 37.72% |
| 2010 FY | 29.38 Billion INR | 37.28% |
| 2009 FY | 21.4 Billion INR | 23.59% |
| 2008 FY | 17.31 Billion INR | -0.47% |
| 2007 FY | 17.39 Billion INR | 118.53% |
| 2006 FY | 7.96 Billion INR | 35.1% |
| 2005 FY | 5.89 Billion INR | 79.15% |
| 2004 FY | 3.28 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | -1388.603% |
| Ind-Swift Limited | 13.45 Billion INR | -180.091% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -674.097% |
| Sakar Healthcare Limited | 1.26 Billion INR | -2882.75% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 75.244% |
| Innova Captab Limited | 4.89 Billion INR | -669.01% |
| Divi's Laboratories Limited | 18.99 Billion INR | -98.423% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -929.21% |
| Morepen Laboratories Limited | 4.45 Billion INR | -744.894% |
| Mankind Pharma Limited | 23.87 Billion INR | -57.826% |
| Sequent Scientific Limited | 8.27 Billion INR | -355.395% |
| Wanbury Limited | 3.15 Billion INR | -1094.115% |
| Laurus Labs Limited | 42.71 Billion INR | 11.785% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -235.891% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -627.296% |
| Alembic Limited | 1.43 Billion INR | -2531.135% |
| Hikal Limited | 12.99 Billion INR | -189.964% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -131.541% |
| Neuland Laboratories Limited | 5.49 Billion INR | -585.279% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -251.891% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 42.129% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -495.372% |
| Themis Medicare Limited | 1.88 Billion INR | -1896.306% |
| RPG Life Sciences Limited | 1.38 Billion INR | -2630.075% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 47.514% |
| Lupin Limited | 96.23 Billion INR | 60.846% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -4707.264% |
| Wockhardt Limited | 39.87 Billion INR | 5.492% |
| Vaishali Pharma Limited | 371.16 Million INR | -10052.006% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -356.694% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -12597.294% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 38.505% |
| FDC Limited | 3.7 Billion INR | -915.863% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 64.774% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -5752.071% |
| Eris Lifesciences Limited | 38.26 Billion INR | 1.535% |
| Venus Remedies Limited | 1.39 Billion INR | -2605.377% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1710.899% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -1686.778% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -23481.109% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -974.866% |
| Shilpa Medicare Limited | 12.93 Billion INR | -191.363% |
| Albert David Limited | 1.15 Billion INR | -3176.265% |
| Ajanta Pharma Limited | 10.71 Billion INR | -251.815% |
| Hester Biosciences Limited | 3.59 Billion INR | -948.218% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -1752.323% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | -167.393% |
| Gufic Biosciences Limited | 5.59 Billion INR | -572.889% |
| Windlas Biotech Limited | 1.76 Billion INR | -2037.658% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -1371.205% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -2087.944% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -1806.607% |
| Granules India Limited | 22.95 Billion INR | -64.154% |
| Aarti Drugs Limited | 11.5 Billion INR | -227.543% |
| Bal Pharma Limited | 2.51 Billion INR | -1400.452% |
| Alkem Laboratories Limited | 48.6 Billion INR | 22.476% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 79.473% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -3406.646% |
| Medicamen Biotech Limited | 940.36 Million INR | -3906.998% |
| Unichem Laboratories Limited | 8.06 Billion INR | -366.964% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -5676.744% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -12947.306% |
| Valiant Laboratories Limited | 1.05 Billion INR | -3460.605% |
| Orchid Pharma Limited | 3.84 Billion INR | -880.222% |
| Medico Remedies Limited | 438.24 Million INR | -8498.062% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -1545.824% |
| Ipca Laboratories Limited | 33.74 Billion INR | -11.67% |
| Brooks Laboratories Limited | 248.6 Million INR | -15057.015% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -3133.791% |
| Piramal Enterprises Limited | 560.47 Billion INR | 93.277% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 54.076% |
| NATCO Pharma Limited | 10.53 Billion INR | -257.771% |
| Suven Life Sciences Limited | 148.62 Million INR | -25253.409% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1167.034% |
| Indoco Remedies Limited | 10.34 Billion INR | -264.334% |
| Alpa Laboratories Limited | 307.12 Million INR | -12168.9% |
| Lasa Supergenerics Limited | 541.92 Million INR | -6853.082% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -867.929% |